Resona Asset Management Co. Ltd. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 238,290 shares of the company’s stock after selling 2,912 shares during the period. Eli Lilly and Company comprises approximately 1.3% of Resona Asset Management Co. Ltd.’s investment portfolio, making the stock its 13th biggest holding. Resona Asset Management Co. Ltd.’s holdings in Eli Lilly and Company were worth $277,178,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Coastal Bridge Advisors LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth $2,959,000. Birinyi Associates Inc. boosted its stake in shares of Eli Lilly and Company by 32.6% in the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock valued at $1,689,000 after purchasing an additional 359 shares during the period. Bridges Investment Management Inc. boosted its stake in shares of Eli Lilly and Company by 38.5% in the third quarter. Bridges Investment Management Inc. now owns 35,294 shares of the company’s stock valued at $40,838,000 after purchasing an additional 9,815 shares during the period. Bernicke Wealth Management Ltd. acquired a new stake in Eli Lilly and Company during the 3rd quarter valued at $5,001,000. Finally, Mosaic Family Wealth Partners LLC grew its holdings in Eli Lilly and Company by 70.6% during the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after purchasing an additional 1,430 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities analysts have commented on LLY shares. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a report on Friday, November 13th. Leerink Partners raised their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. UBS Group raised their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a research note on Friday, October 30th. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,650.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. Finally, Citigroup boosted their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,422.00.
Read Our Latest Research Report on LLY
Latest Eli Lilly and Company News
These are some of the LLY news items that stood out recently:
- Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, potentially broadening the drug’s use and commercial opportunity. Article: Health Canada approves Lilly’s Mounjaro
- Neutral Sentiment: Recent updates cover studies of brenipatide, LY3839056, tirzepatide, and the cost of Alzheimer’s care. The reports describe study activity or updates, but the supplied information does not identify new efficacy results, so their near-term effect on valuation is unclear. Article: Lilly tests brenipatide in a depression study
- Negative Sentiment: Some coverage warns that Lilly’s roughly $1.4 trillion valuation leaves substantial expectations embedded in the shares. That could make the stock more sensitive to any slowdown in growth or disappointing clinical results. Article: Eli Lilly’s valuation is heavy with hope
Eli Lilly and Company Stock Down 0.3%
Shares of NYSE:LLY opened at $1,346.40 on Friday. The firm has a market cap of $1.27 trillion, a PE ratio of 43.70, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. The company has a fifty day simple moving average of $1,268.06 and a 200 day simple moving average of $1,119.25. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,475.25.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm’s revenue was up 38.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $7.02 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 35.72 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.
Insider Buying and Selling
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
